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Cancer awareness public campaigns aim to shorten the interval between symptom onset and presentation to a doctor (the
‘patient interval’). Appreciating variation in promptness of presentation can help to better target awareness campaigns. We
explored variation in patient intervals recorded in consultations with general practitioners among 10,297 English patients sub-
sequently diagnosed with one of 18 cancers (bladder, brain, breast, colorectal, endometrial, leukaemia, lung, lymphoma, mela-
noma, multiple myeloma, oesophageal, oro-pharyngeal, ovarian, pancreatic, prostate, renal, stomach, and unknown primary)
using data from of the National Audit of Cancer Diagnosis in Primary Care (2009–2010). Proportions of patients with
‘prompt’/‘non-prompt’ presentation (0–14 or 151 days from symptom onset, respectively) were described and respective
odds ratios were calculated by multivariable logistic regression. The overall median recorded patient interval was 10 days
(IQR 0–38). Of all patients, 56% presented promptly. Prompt presentation was more frequent among older or housebound
patients (p < 0.001). Prompt presentation was most frequent for bladder and renal cancer (74% and 70%, respectively); and
least frequent for oro-pharyngeal and oesophageal cancer (34% and 39%, respectively, p <.001). Using lung cancer as refer-
ence, the adjusted odds ratios of non-prompt presentation were 2.26 (95% confidence interval 1.57–3.25) and 0.42 (0.34–
0.52) for oro-pharyngeal and bladder cancer, respectively. Sensitivity analyses produced similar findings. Routinely recorded
patient interval data reveal considerable variation in the promptness of presentation. These findings can help to prioritise
public awareness initiatives and research focusing on symptoms of cancers associated with greater risk of non-prompt presen-
tation, such as oro-pharyngeal and oesophageal cancer.
Diagnosing cancer promptly in symptomatic patients is a key
aspect of contemporary cancer control policies in different
countries.1–5 After symptom onset, delays in establishing the
diagnosis may occur both before a patient presents to a doctor
and post-presentation.6 In most cancer patients, initial symp-
toms have low specificity, as they are also associated with
benign diseases.7 Appropriate appraisal and interpretation of
symptoms that may be related to cancer by both patients (pre-
presentation) and their doctor (post-presentation) are critical
for timely diagnosis.6,8 There is large variation between differ-
ent patient groups in the promptness with which general prac-
titioners suspect the diagnosis of cancer and refer patients to
specialists (i.e. in the ‘primary care interval’).9,10 It is also plau-
sible that there is variation in the promptness with which can-
cer patients seek medical help (i.e. in the ‘patient interval’,
defined as the period between first symptom onset and first
relevant presentation to a doctor6). Variation in the patient
interval may exist both between patients with different socio-
demographic characteristics (since cancer awareness, beliefs
and attitudes vary between socio-demographic groups or
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country populations11–16; and between patients with different
cancers (given wide variability in the nature of symptoms of
different tumours). Understanding variation in the patient
interval can help to identify patient groups at higher risk of
non-prompt presentation, enabling better targeting of public
health awareness interventions.17
Evidence about patient interval variation is however lim-
ited, partly because accurate measurement is known to be
challenging.6,18 Determining the date of onset of symptoms
or bodily changes (the start of the patient interval) is difficult,
given the potential for inaccurate or biased patient recall, and
the gradual onset of many symptoms.6,18 The date of first
presentation to a doctor with symptoms caused by cancer
(the end of the patient interval) is often easy to identify, but
there can be difficulties in determining the first relevant con-
sultation in patients with multi-morbidity. Acknowledging
these difficulties, broadly, patient interval information can be
obtained either from the patients themselves (through inter-
views or questionnaire surveys19–22 or from their medical
consultation records.23,24 Either approach has advantages and
disadvantages (Box). Although elicitation of symptom dura-
tion typically forms a key part of medical consultations, med-
ical records studies assume accurate elicitation and recording
of this information. On the other hand, patient interview or
questionnaire studies can provide detailed information but
may lack representativeness (as, by their nature, cancer
patients who die early or are too sick soon after diagnosis are
typically not included in such studies).
Appreciating both the strengths and the limitations of
patient interval studies that are based on information from
medical records, we conducted a secondary analysis of data
from the National Audit of Cancer Diagnosis in Primary Care,
2009–2010.25 Our aim was to explore variation in the routinely
recorded (i.e. during general practice consultations) patient
interval of patients subsequently diagnosed with cancer. We
were particularly interested in exploring likely variation by
socio-demographic characteristic and cancer diagnosis.
Material and Methods
Data
We analysed data from the (English) National Audit of Can-
cer Diagnosis in Primary Care (2009–2010).25 Information
from patient records on different aspects of the diagnostic
process was collected by general practitioners or other pri-
mary care professionals in an estimated total of 1,170 gen-
eral practices (14% of all practices in England).25,26
Audited patients were incident cases of cancer within the
audit period and were representative of the age and diagno-
sis case-mix of English cancer patients.25 Although participa-
tion to the audit was voluntary, the organisational
characteristics and care quality of participating and non-
participating practices were similar.27 Screening-detected
cases were excluded from the audit. The patient interval was
defined as the number of days from first symptom onset to
first presentation to a general practitioner with relevant
symptoms based on information in the patients’ records.6,25
Patients were categorised as housebound if primary care
encounters usually occurred at home – we included informa-
tion on housebound status in the analysis as a marker of
severe co-morbidity, because of theoretical concerns that
patients with higher levels of co-morbidity may be disadvan-
taged in respect of the timeliness of cancer diagnosis. The
analysis was a priori restricted to patients who first pre-
sented to a general practitioner with any of 18 cancers for
What’s new?
A critical aspect of cancer diagnosis is how promptly patients consult a doctor after they first notice initial symptoms. Here,
the authors examine differences in this so-called patient interval in English patients subsequently diagnosed with one of 18
cancers. On average, patients with bladder and renal cancer as well as older and housebound patients consulted a doctor rel-
atively promptly while patients with oro-pharyngeal and oesophageal cancer took the longest until first presenting to a gen-
eral practitioner. The authors point out that cancer awareness campaigns should encompass symptoms of oro-pharyngeal and
oesophageal cancer aiming to shorten the patient interval for these cancers.
Box. Principal advantages and limitations of the two main approaches to measuring the patient interval
Strengths Limitations
Patient interview
(or questionnaire) studies
Potentially highly accurate and detailed
Can allow for detailed (‘in-depth’) appreciation
of relevant symptoms and their time of onset.
Limited representativeness (generalisability)
Patients dying soon after symptom onset/
diagnosis and those ‘too ill to take part’
are unlikely to be included.
Studies of medical
consultation records
High representativeness (generalisability)
Information about all cancer patients can be
included, even for those with poor prognosis/
only short-term survival.
Potential limitations in completeness
and accuracy
Rely on doctors appropriately eliciting the
timing of symptom onset as part of history
taking and accurately interpreting and recording
this information. Patient interval information
may be missing.
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which variation in respect of the primary care interval was
previously explored and were aged 15 or older.25,26 Analysis
was restricted to records with patient interval values of up to
two years, and complete information on outcome and expo-
sure variables of interest (Fig. 1).
Analysis
We aimed to profile variation in promptness of presentation
to a general practitioner after symptom onset. There is no uni-
form approach to analysing patient interval data, which tend
to be zero-inflated and right-skewed. Therefore, we first
described the key patient interval statistics (median and other
relevant centile values) by patient group. Subsequently, we
analysed variation in respect of a binary form of the patient
interval (0–14 vs 15 or more days – hereafter, we use the terms
prompt/non-prompt to denote either category, respectively).
Our choice of binary cut-off was pragmatic – choosing a
short-term period during which it could be reasonably
assumed that most patients who did decide to see their doctor
would have been able to do so. Additional short-term binary
cut-off values were explored in sensitivity analysis (see below).
In univariable analysis, we examined crude differences
between different patient groups in respect of the median
patient interval, the proportion of non-prompt presenters
and respective crude odds ratios. Subsequently, multivariable
logistic regression was used to explore independent associa-
tions between patient characteristics or cancer diagnosis and
prompt/non-prompt presentation. Further, interactions
between cancer diagnosis and age and cancer diagnosis
and gender were explored. Robust estimation of standard
errors was used to account for potential clustering of
observations.
Sensitivity analysis
We first repeated the multivariable regression model using
alternative binary categories of the patient interval (0–7 vs
81, 0–21 vs 221 and 0–30 vs 311 days, respectively). Com-
plete case analysis pre-supposes that missing information is
Missing Completely At Random which is a strong assump-
tion. We, therefore, used extreme-case scenario analysis
(assuming data are Missing Not At Random) by repeating
the multivariable analysis assuming patients with missing
interval values were either ‘all non-prompt’ or ‘all prompt’
presenters – these analyses do not intend to represent a real
situation but are useful to illustrate the largest possible bias
that could be introduced by missing patient interval informa-
tion. We used further sensitivity analyses to explore potential
confounding by ethnic group among patients with known
ethnicity and the impact of only including patients with
interval values of up to a year. Analysis was undertaken using
Stata 11 (Stata Corporation, Texas).
Results
Of an initial 14,320 patients with one of the 18 cancers
examined, 10,297 (72%) were included in complete case anal-
ysis (Fig. 1). The main single source of sample attrition was
missing patient interval (3,004 or 21% of initially eligible
patients). Patients with missing patient interval were more
likely to be older and men (p < 0.001 for both) without evi-
dence for an association with housebound status (p 5 0.342).
Missing patient interval also varied by cancer (p < 0.001),
being most common among patients with leukaemia, prostate
cancer, melanoma and multiple myeloma (41%, 40%, 36%
and 28%, respectively, Supporting Information Appendix 1).
Hereafter, results related to complete case analysis except
were otherwise noted. Characteristics of included patients are
shown in Table 1.
The overall median patient interval was 10 days (inter-
quartile range 0–38 days); about half of all patients (5,789,
or 56%) had an interval of up to 14 days, i.e. were prompt
presenters by our definition (Table 1). There was substantial
variation in promptness of presentation by age, housebound
status and cancer diagnosis (p < 0.001 for all). Prompt pre-
sentation was more frequent among older patients; and
those who were housebound (66% vs 56% among those
non-housebound). These differences were also apparent
when examining various centiles of the patient interval
which tended to be shorter for older and housebound
patients (Table 1). Prompt presentation was most frequent
Figure 1. Derivation of the analysis sample. Percentage values
relate to the initial sample of 14,320 patients with one of the 18
studied cancers.
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among patients with bladder and renal cancer (74% and
70%, respectively). Conversely, oro-pharyngeal and oesopha-
geal cancer had the lowest proportions of prompt presenters
(34% and 39%, respectively).
Table 2 and Figures 2 and 3 describe odds ratios of non-
prompt presentation derived by both univariable and multi-
variable logistic regression. Except for gender for which there
was no evidence of variation in the multivariable analysis (p 5
0.17), these analyses produced similar findings, indicating only
a limited degree of confounding between exposure variables.
The largest degree of variation (>5-fold) in the odds of
prompt presentation is seen between patients with different
Table 1. Sample characteristics and descriptive statistics for patient interval by patient characteristic and cancer (n 5 10,297)
Patient interval (days)
Patient interval binary category
Prompt
(0–14 days)
Non-prompt
(151 days)
N
25th
Centile Median
75th
Centile
90th
Centile
95th
Centile p-Value1 N % N % p-Value2
Age
15–44 784 1 13 42 120 242 p < 0.0001 439 56.0 345 44.0 p < 0.0001
45–54 1,220 1 14 45 108 187 649 53.2 571 46.8
55–64 2,170 0 12 41 102 191 1,186 54.7 984 45.3
65–74 2,807 0 11 43 112 185 1,526 54.4 1,281 45.6
75–84 2,459 0 7 31 92 183 1,463 59.5 996 40.5
851 857 0 7 31 95 188 526 61.4 331 38.6
Sex
Male 5,028 0 11 43 116 200 p 5 0.37 2,742 54.5 2,286 45.5 p 5 0.0008
Female 5,269 0 10 33 92 182 3,047 57.8 2,222 42.2
Cancer
Bladder 601 0 2 16 67 141 p < 0.0001 446 74.2 155 25.8 p < 0.0001
Renal 209 0 3 19 74 184 146 69.9 63 30.1
Brain 125 1 7 26 96 154 81 64.8 44 35.2
Breast 2,124 1 7 27 77 164 1371 64.5 753 35.5
Unknown
primary
110 0 7 23 64.5 104 69 62.7 41 37.3
Leukaemia 239 0 7 30 86 140 144 60.3 95 39.7
Prostate 1,386 0 6 42 151 283 813 58.7 573 41.3
Pancreatic 272 1 9.5 31 73 97 162 59.6 110 40.4
Stomach 187 0 9 33 125 205 104 55.6 83 44.4
Lung 1,126 0 12 33 87 138 622 55.2 504 44.8
Myeloma 127 0 14 40 95 193 69 54.3 58 45.7
Endometrial 311 1 14 57 152 259 165 53.1 146 46.9
Ovarian 270 2 14 51 113.5 172 144 53.3 126 46.7
Lymphoma 482 1 14 43 92 183 243 50.4 239 49.6
Melanoma 477 0 20 69 241 366 216 45.3 261 54.7
Colorectal 1,697 1 19 60 131 203 786 46.3 911 53.7
Oesophageal 407 7 22 46 99 152 158 38.8 249 61.2
Oro-pharyngeal 147 7 30 62 122 212 50 34.0 97 66.0
Housebound status
No 9,707 0 11 39 103 188 p < 0.0001 5399 55.6 4308 44.4 p < 0.0001
Yes 590 0 5 28 91 200 390 66.1 200 33.9
Total 10,297 0 10 38 103 189 5,789 56.2 4,508 43.8
1Kruskal–Wallis test.
2Chi-squared test.
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cancers. Specifically, using patients with lung cancer as the ref-
erence group, the odds ratios of non-prompt presentation
were 2.26 (95% confidence interval 1.57–3.25) and 0.42 (0.34–
0.52) for patients with oro-pharyngeal and bladder cancer,
respectively. There was no evidence of interaction between
cancer diagnosis and either age or sex (p 5 0.29 for both).
Sensitivity analysis
Using different binary categories of patient interval produced
similar findings (Supporting Information Appendix 2).
Assuming patients with missing data were either ‘all non-
prompt’ or ‘all prompt’ presenters did either attenuate or
accentuate patterns of variation observed in the main analy-
sis, respectively, particularly by age and the four cancers with
relatively high proportions of missing interval data (leukae-
mia, prostate, melanoma and myeloma) (Supporting Infor-
mation Appendix 3). The degree of confounding by ethnicity
was very limited (Supporting Information Appendix 4). Only
including patients with interval values of up to a year pro-
duced highly concordant findings (results not shown).
Discussion
In this study, among patients with any of the 18 cancers
prompt presentation was most frequent among those with
Table 2. Proportion of patients with non-prompt presentation and respective unadjusted and adjusted odds ratios (n 5 10,297)
% Non-prompt
(151 days)
presentation1
Unadjusted odds ratios for non-
prompt (151 days) presentation
Adjusted odds ratios for non-prompt
presentation (151 days) by patient
characteristic and cancer diagnosis
Age
15–44 (N 5 784) 44.0 0.94 (0.80–1.10) p < 0.0001 0.99 (0.84–1.17) p 5 0.0003
45–54 (N 5 1,220) 46.8 1.05 (0.92–1.20) 1.12 (0.98–1.30)
55–64 (N 5 2,170) 45.3 0.99 (0.88–1.11) 0.98 (0.87–1.10)
65–74 (N 5 2,807) 45.6 Baseline Baseline
75–84 (N 5 2,459) 40.5 0.81 (0.73–0.90) 0.83 (0.74–0.93)
851 (N 5 857) 38.6 0.75 (0.64–0.88) 0.83 (0.70–0.98)
Gender
Male (N 5 5,028) 45.5 Baseline p 5 0.0008 Baseline p 5 0.17
Female (N 5 5,269) 42.2 0.87 (0.81–0.95) 0.93 (0.84–1.03)
Cancer type
Bladder (N 5 601) 25.8 0.43 (0.35–0.53) p < 0.0001 0.42 (0.34–0.52) p < 0.0001
Renal (N 5 209) 30.1 0.53 (0.39–0.73) 0.51 (0.37–0.71)
Brain (N 5 125) 35.2 0.67 (0.46–0.99) 0.66 (0.45–0.98)
Breast (N 5 2,124) 35.5 0.68 (0.58–0.79) 0.67 (0.57–0.78)
Unknown primary (N 5 110) 37.3 0.73 (0.49–1.10) 0.75 (0.50–1.12)
Leukaemia (N 5 239) 39.7 0.81 (0.61–1.08) 0.78 (0.58–1.03)
Prostate (N 5 1,386) 41.3 0.87 (0.74–1.02) 0.83 (0.70–0.98)
Pancreatic (N 5 272) 40.4 0.84 (0.64–1.10) 0.85 (0.65–1.11)
Stomach (N 5 187) 44.4 0.98 (0.72–1.34) 0.99 (0.73–1.35)
Lung (N 5 1,126) 44.8 Baseline Baseline
Myeloma (N 5 127) 45.7 1.04 (0.72–1.50) 1.01 (0.70–1.47)
Endometrial (N 5 311) 46.9 1.09 (0.85–1.40) 1.08 (0.84–1.40)
Ovarian (N 5 270) 46.7 1.08 (0.83–1.41) 1.09 (0.83–1.43)
Lymphoma (N 5 482) 49.6 1.21 (0.98–1.50) 1.15 (0.93 - 1.43)
Melanoma (N 5 477) 54.7 1.49 (1.20–1.85) 1.41 (1.13–1.75)
Colorectal (N 5 1,697) 53.7 1.43 (1.23–1.66) 1.43 (1.23–1.67)
Oesophageal (N 5 407) 61.2 1.94 (1.54–2.45) 1.94 (1.54–2.45)
Oropharynheal (N 5 147) 66.0 2.39 (1.67–3.43) 2.26 (1.57–3.25)
Housebound
No (N 5 9,707) 44.4 Baseline p < 0.0001 Baseline p < 0.0001
Yes (N 5 590) 33.9 0.64 (0.54–0.77) 0.67 (0.56–0.81)
1This column repeats information presented in Table 1, for ease of reference regarding crude proportions.
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bladder and renal cancer, and least frequent among patients
with oro-pharyngeal and oesophageal cancer. Prompt presen-
tation was also more frequent in older and housebound
patients.
Of the 18 cancers included in our study, 12 were also
examined previously by an audit (medical record) study of
Scottish patients23; and 10 by a similar Danish study.24
Among Scottish cancer patients, those with ‘head and neck’
(including oro-pharyngeal) cancer presented least promptly,
whilst those with bladder and ‘other urological’ (including
renal) cancers did so most promptly.23 In general, median
reported patient interval values for Scottish patients were
similar to those reported here; however, those reported for
Danish patients were longer – potentially reflecting differen-
ces in patient populations or in methods of data recording
and collection (Supporting Information Appendix 5).23,24
However, the Spearman rank correlation coefficient for pair-
wise comparisons of median patient interval values by cancer
is 0.87 (p 5 0.0002) and 0.59 (p 5 0.071) between the pres-
ent and the Scottish or the Danish study, respectively – indi-
cating an overall high degree of rank concordance.23,24
Similarly, most Finnish patients with pharyngeal cancer have
patient intervals longer than a month.28
Prior evidence is inconsistent regarding the presence and
direction of associations between age and patient interval for
different cancers.22,28–32 We are unaware of previous descrip-
tions of variation in patient interval by housebound status.
Housebound patients may be more prone to seeking help
promptly, or are monitored more frequently and, therefore,
assessed more promptly. Disability may confer paradoxical
benefits in respect of stage at diagnosis of cancer.33
One of the strengths of our study is that it included
patients with many different cancers. The representativeness
of the patient population and of participating practices was
good.25,27 Because of continuous sampling, the study popula-
tion can be assumed to be a relatively unbiased sample of
incident cases first presenting to general practitioners, also
including patients with poor prognosis. The robustness of the
findings was explored by a range of sensitivity analyses,
which generally provided similar findings. Although patient
interval data were missing for between a fifth and a quarter
of patients, sensitivity analyses using extreme-case assump-
tions indicated that this factor might have biased the findings
regarding patients with four cancers with a relatively high
proportion of missing data (leukaemia, prostate cancer, mela-
noma and myeloma); in contrast, patterns of variation for
patients with all other cancers, and particularly for those
with bladder, renal, oesophageal and oro-pharyngeal cancer,
remained similar. Two of the cancers with higher than aver-
age proportion of missing patient interval data were prostate
cancer and leukaemia. For those cancers, diagnostic suspicion
is sometimes first raised at an asymptomatic stage or inciden-
tally, based on the findings of relatively simple-to-perform
blood tests (such as Prostate Specific Antigen testing or Full
Blood Count). In such circumstances, the diagnosis is not
symptom-driven and, therefore, measurement of the patient
interval is a priori not applicable. These factors may explain
the higher proportion of missing interval information for
those cancers.
There are several limitations. The validity of patient inter-
val data is contingent on several factors: patients need to
have been able to accurately appreciate the onset of their
symptoms and recall relevant dates; their doctors need to
have been able to elicit and appropriately interpret informa-
tion about the patient interval during consultations, and to
have accurately entered it in the patient records. Although
elicitation of information on symptom duration is a key
aspect of a medical consultation, inaccuracies and omissions
may occur in any of the above steps. However, previous
research indicates that inaccurate patient recall of diagnostic
intervals is unlikely to be systematic (e.g. biased towards
either over- or under-estimation of patient interval).34 It is
Figure 3. Multivariable logistic regression outputs (adjusted odds
ratios and 95% confidence intervals) for non-prompt presentation
by cancer diagnosis (n 5 10,297).
Figure 2. Multivariable logistic regression outputs (adjusted odds
ratios and 95% confidence intervals) for non-prompt presentation
by sociodemographic characteristic (n 5 10,297).
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also unreasonable to assume that recall inaccuracies will be
grossly differential between patients with different cancers –
for example, between patients with bladder and oro-
pharyngeal cancer, given the large size of the observed varia-
tion between these cancers (5-fold difference in odds
ratios). Although we believe this assertion to be reasonable,
there is no direct evidence for it, and future evidence from
relevant clinical psychology studies would be useful. It is
important to also consider that non-systematic errors of this
kind would result in under-estimation of true variation;
therefore, our reported estimates of socio-demographic or
cancer diagnosis differences may be conservative. We were
not able to examine variation in the patient interval of
patients with cancer whose first presentation did not involve
previous contact with their general practitioner. Some
patients have long or very long patient intervals, e.g. 90 or
180 days (Table 1) and the predictors of very long patient
intervals may be different to the predictors of delay in respect
of shorter intervals. We plan to explore variation in the
patient interval amongst these patients in the future. Our
findings relate to a population of English cancer patients, and
extrapolations to other populations should therefore be cau-
tious. Although at least some of the observed findings may
be relevant, research questions about variation in the patient
interval in other country populations are best addressed by
new empirical evidence.
Promptness of presentation is a concept also applicable to
a larger group of patients who experience symptoms but do
not necessarily have cancer (or any other formal diagnosis).
For example, even among patients with ‘alarm’ symptoms
mandating specialist referral for investigation of suspected
cancer, only one in nine are found to have cancer, whereas
eight in nine patients with relevant symptoms will have
another diagnosis.35 Therefore, future research should also
explore variation in the timeliness of presentation among the
broader population of patients with symptoms likely to be
related to cancer, and not only among cancer cases. Although
clearly important, exploring variation in patient interval
among patients with symptoms (not simply among cancer
patients) was impossible given our data.14
Measuring patient interval is challenging as it cannot be
‘objectively’ measured.6,18,36 Additional difficulties arise in the
context of co-morbidity. Both patient interviews/surveys and
medical record studies have strengths and limitations (Box).
Patient interview/questionnaire studies can be subject to sur-
vivorship bias (differential attrition) as those who die early
do not contribute information and their intervals may be dif-
ferent to those of survivors. In contrast, studies based on
medical records information can provide for relatively large
samples (including patients with rarer cancers) whilst limiting
the potential for survivorship bias (as continuous sampling of
all incident cases is possible). Ideally studies should encom-
pass both approaches, and also measure patient intervals of
patients with relevant symptoms who do not necessarily have
cancer, as in the DISCOVERY programme’s SYMPTOM
study, due to report 2014 (http://discovery-programme.org/
symptom_study.php).
Variation in the promptness of presentation by cancer is
likely to reflect differences in how patients appreciate and
appraise typical symptoms of different cancers. Symptoms
with abrupt and unexplained onset such as bleeding are asso-
ciated with shorter patient intervals.22,29–31 As patients with
bladder and renal cancer often present with haematuria, this
may explain why patients with these two cancers seem to
present more promptly than patients with any other exam-
ined cancer.23 Other factors, such as symptom frequency,
duration and intensity may also matter. Familiarity with signs
and symptoms in the context of previous self-limiting illness
(e.g. oral ulcerations) has been judged responsible for non-
prompt presentation of patients with oro-pharyngeal
cancer.37,38
Whilst there is very strong evidence of variation in
prompt presentation between patients with different cancers
we cannot reliably distinguish between all individual cancers,
particularly for cancers in the middle of the spectrum. We
suggest that interpretation considers the general pattern of
variation, particularly focusing on comparisons of the
extremes (e.g. oro-pharyngeal or oesophageal vs bladder or
renal cancer). We specifically draw attention to oro-
pharyngeal and oesophageal cancer – the two cancers with
the highest proportions of non-prompt presenters and lon-
gest median patient intervals. Oro-pharyngeal cancer has rel-
atively poor 5-year relative survival (typically <50% for most
sub-sites except lip). Together with our own findings, these
considerations can support the development of awareness
campaigns for oro-pharyngeal cancer.39 Oesophageal cancer
also has poor prognosis (5-year relative survival <20%).
Although dysphagia is a common cardinal symptom of oeso-
phageal cancer (and one with relatively high specificity40, the
findings indicate that patients with oesophageal cancer do
not present promptly. These findings concord with prior evi-
dence indicating that awareness of ‘difficulty swallowing’ as a
potential sign of cancer is particularly poor among members
of the British public (lowest compared with other eight can-
cer symptoms).11 Specifically, only about 1 in 20 respondents
would immediately recall dysphagia as a symptom of cancer
– in contrast lump/swelling (the symptom with the highest
spontaneous recall) would be recalled by two thirds of
respondents.11 These findings would therefore support the
development of awareness campaigns about the importance
of dysphagia. The clinical and population health outcomes of
awareness campaigns nevertheless need to be evaluated,
ideally using controlled designs.41
As the aim of public awareness interventions is to
decrease patient intervals,17 we strongly advocate the conduct
of regular surveys of patient interval in representative sam-
ples of cancer patients to help monitor the impact of such
interventions and progress towards improving the timeliness
of presentation in the population. Appreciating variation in
promptness of presentation can help to better target and
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tailor such interventions. Given the findings, prioritising pub-
lic awareness interventions for symptoms of oro-pharyngeal
and oesophageal cancer is particularly justified.
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